JP2020515577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515577A5 JP2020515577A5 JP2019553112A JP2019553112A JP2020515577A5 JP 2020515577 A5 JP2020515577 A5 JP 2020515577A5 JP 2019553112 A JP2019553112 A JP 2019553112A JP 2019553112 A JP2019553112 A JP 2019553112A JP 2020515577 A5 JP2020515577 A5 JP 2020515577A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 54
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 44
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 44
- 102000036639 antigens Human genes 0.000 claims description 44
- 108091007433 antigens Proteins 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 44
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 229960004641 rituximab Drugs 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000005847 immunogenicity Effects 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 57
- 239000003937 drug carrier Substances 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022211248A JP2023052145A (ja) | 2017-03-27 | 2022-12-28 | 免疫原性の低下のための方法及び組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477257P | 2017-03-27 | 2017-03-27 | |
| US62/477,257 | 2017-03-27 | ||
| PCT/US2018/024316 WO2018183182A1 (en) | 2017-03-27 | 2018-03-26 | Methods and compositions for reduction of immunogenicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211248A Division JP2023052145A (ja) | 2017-03-27 | 2022-12-28 | 免疫原性の低下のための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515577A JP2020515577A (ja) | 2020-05-28 |
| JP2020515577A5 true JP2020515577A5 (enExample) | 2021-05-13 |
| JP7237848B2 JP7237848B2 (ja) | 2023-03-13 |
Family
ID=62002401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553112A Active JP7237848B2 (ja) | 2017-03-27 | 2018-03-26 | 免疫原性の低下のための方法及び組成物 |
| JP2022211248A Pending JP2023052145A (ja) | 2017-03-27 | 2022-12-28 | 免疫原性の低下のための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022211248A Pending JP2023052145A (ja) | 2017-03-27 | 2022-12-28 | 免疫原性の低下のための方法及び組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200330590A1 (enExample) |
| EP (1) | EP3601351A1 (enExample) |
| JP (2) | JP7237848B2 (enExample) |
| KR (1) | KR20190133198A (enExample) |
| CN (1) | CN110612309A (enExample) |
| AU (1) | AU2018244276A1 (enExample) |
| BR (1) | BR112019020185A2 (enExample) |
| CA (1) | CA3057841A1 (enExample) |
| CL (1) | CL2019002716A1 (enExample) |
| CO (1) | CO2019011640A2 (enExample) |
| EA (1) | EA201992278A1 (enExample) |
| IL (1) | IL269590A (enExample) |
| MX (1) | MX2019011624A (enExample) |
| SG (1) | SG11201908678XA (enExample) |
| WO (1) | WO2018183182A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
| KR20170110601A (ko) | 2015-02-05 | 2017-10-11 | 몰레큘러 템플레이츠, 인코퍼레이션. | 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물 |
| KR20200143634A (ko) | 2018-04-17 | 2020-12-24 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자 |
| TW202104260A (zh) | 2019-04-05 | 2021-02-01 | 美商西建公司 | 腫瘤選擇性結合ｃｄ４７之抗體之工程 |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| NZ786589A (en) * | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| EP4089114A1 (en) * | 2020-01-09 | 2022-11-16 | Innovent Biologics (Suzhou) Co., Ltd. | Application of combination of anti-cd47 antibody and anti-cd20 antibody in preparation of drugs for preventing or treating tumors |
| WO2022076987A1 (en) | 2020-10-07 | 2022-04-14 | Celgene Corporation | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
| JP2023552375A (ja) | 2020-12-06 | 2023-12-15 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための多量体 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| EP0799244A1 (en) | 1995-10-16 | 1997-10-08 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| KR100353304B1 (ko) | 1996-10-01 | 2002-09-30 | 에스알아이 인터내셔널 | 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법 |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AU2161501A (en) | 1999-11-29 | 2001-06-25 | Unilever Plc | Immobilized single domain antigen-binding molecules |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| AU2004280333A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Llc | Humanization of antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EP3505534A1 (en) | 2012-06-08 | 2019-07-03 | Sutro Biopharma, Inc. | Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use |
| ES2728864T3 (es) | 2012-08-31 | 2019-10-29 | Sutro Biopharma Inc | Aminoácidos modificados que comprenden un grupo azido |
| MX2015007446A (es) * | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| NZ710695A (en) * | 2013-02-06 | 2020-05-29 | Inhibrx Inc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| HK1245154A1 (zh) * | 2014-12-30 | 2018-08-24 | 细胞基因公司 | 抗cd47抗体及其用途 |
| CN108290948B (zh) * | 2015-09-21 | 2021-10-29 | 伊拉兹马斯大学医疗中心 | 抗-cd47抗体及使用方法 |
-
2018
- 2018-03-26 CN CN201880029818.2A patent/CN110612309A/zh active Pending
- 2018-03-26 AU AU2018244276A patent/AU2018244276A1/en not_active Abandoned
- 2018-03-26 EA EA201992278A patent/EA201992278A1/ru unknown
- 2018-03-26 WO PCT/US2018/024316 patent/WO2018183182A1/en not_active Ceased
- 2018-03-26 EP EP18718270.4A patent/EP3601351A1/en not_active Withdrawn
- 2018-03-26 JP JP2019553112A patent/JP7237848B2/ja active Active
- 2018-03-26 SG SG11201908678X patent/SG11201908678XA/en unknown
- 2018-03-26 US US16/498,063 patent/US20200330590A1/en not_active Abandoned
- 2018-03-26 MX MX2019011624A patent/MX2019011624A/es unknown
- 2018-03-26 KR KR1020197030975A patent/KR20190133198A/ko not_active Ceased
- 2018-03-26 BR BR112019020185-8A patent/BR112019020185A2/pt not_active Application Discontinuation
- 2018-03-26 CA CA3057841A patent/CA3057841A1/en active Pending
-
2019
- 2019-09-24 IL IL26959019A patent/IL269590A/en unknown
- 2019-09-24 CL CL2019002716A patent/CL2019002716A1/es unknown
- 2019-10-21 CO CONC2019/0011640A patent/CO2019011640A2/es unknown
-
2022
- 2022-12-28 JP JP2022211248A patent/JP2023052145A/ja active Pending
-
2023
- 2023-06-15 US US18/335,656 patent/US20240075133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515577A5 (enExample) | ||
| JP2008540447A5 (enExample) | ||
| JP2020527332A5 (enExample) | ||
| JP2020520370A5 (enExample) | ||
| JP2008530142A5 (enExample) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2021531764A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JPWO2019246514A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JP2019529373A5 (ja) | 抗Ｔｉｍ−３抗体 | |
| JP2020501531A5 (enExample) | ||
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| JP2017501157A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2017534256A5 (enExample) | ||
| JP2016503067A5 (enExample) | ||
| CA3232806A1 (en) | B7-h4 antibody-drug conjugates for the treatment of cancer | |
| JPWO2019223733A5 (enExample) | ||
| JPWO2020127503A5 (enExample) | ||
| JPWO2019246356A5 (enExample) |